Grufity logoGrufity logo
StocksFundsScreenerSectorsWatchlists
AKBA

AKBA - Akebia Therapeutics Inc Stock Price, Fair Value and News

1.39USD-0.03 (-2.11%)Market Closed
Watchlist

Market Summary

USD1.39-0.03
Market Closed
-2.11%

AKBA Stock Price

View Fullscreen

AKBA RSI Chart

AKBA Valuation

Market Cap

267.5M

Price/Earnings (Trailing)

-4.56

Price/Sales (Trailing)

1.06

EV/EBITDA

-3.2

Price/Free Cashflow

-3.53

AKBA Price/Sales (Trailing)

AKBA Profitability

Operating Margin

80.92%

EBT Margin

-34.75%

Return on Equity

-3.73%

Return on Assets

-24.94%

Free Cashflow Yield

-28.32%

AKBA Fundamentals

AKBA Revenue

Revenue (TTM)

271.1M

Rev. Growth (Yr)

-13.69%

Rev. Growth (Qtr)

2.34%

AKBA Earnings

Earnings (TTM)

-58.6M

Earnings Growth (Yr)

73.22%

Earnings Growth (Qtr)

-29.69%

Breaking Down AKBA Revenue

Last 7 days

-11.6%

Last 30 days

-6.4%

Last 90 days

45%

Trailing 12 Months

81.3%

How does AKBA drawdown profile look like?

AKBA Financial Health

Current Ratio

1.38

Debt/Equity

0.02

Debt/Cashflow

-2.19

AKBA Investor Care

Shares Dilution (1Y)

2.41%

Diluted EPS (TTM)

-0.33

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
2023271.1M000
2022221.0M294.9M294.8M292.7M
2021258.5M221.2M210.0M211.7M
2020350.8M340.2M308.2M294.6M
2019234.5M286.5M325.3M335.0M
2018203.0M223.3M235.2M207.7M
201731.8M62.0M92.2M178.0M
2016860.1K1.1M1.3M1.5M
2015612.2K525.2K410.2K635.2K
2014942.8K835.8K777.8K700.2K
20131.7M1.5M1.3M1.0M
20120002.0M

Tracking the Latest Insider Buys and Sells of Akebia Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Feb 01, 2024
burke steven keith
sold
-40,842
1.68
-24,311
svp, chief medical officer
Feb 01, 2024
butler john p.
sold
-78,101
1.68
-46,489
ceo and president
Jan 31, 2024
hadas nicole r.
acquired
-
-
149,300
svp, chief legal officer
Jan 31, 2024
grund nicholas
acquired
-
-
303,300
chief commercial officer
Jan 31, 2024
butler john p.
acquired
-
-
603,500
ceo and president
Jan 31, 2024
dahan michel
acquired
-
-
149,300
svp, chief operating officer
Jan 31, 2024
snow ellen
acquired
-
-
149,300
svp, cfo and treasurer
Jan 31, 2024
burke steven keith
acquired
-
-
202,200
svp, chief medical officer
Jan 31, 2024
malabre richard c
acquired
-
-
223,950
chief accounting officer
Jul 31, 2023
snow ellen
acquired
-
-
370,000
svp, cfo and treasurer

1–10 of 50

Which funds bought or sold AKBA recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
Feb 16, 2024
PRICE T ROWE ASSOCIATES INC /MD/
unchanged
-
6,000
75,000
-%
Feb 15, 2024
JANE STREET GROUP, LLC
added
62.11
52,358
120,953
-%
Feb 15, 2024
MERCER GLOBAL ADVISORS INC /ADV
reduced
-1.37
1,000
24,000
-%
Feb 15, 2024
State of Wyoming
reduced
-46.32
-35,112
49,259
0.01%
Feb 14, 2024
TWO SIGMA SECURITIES, LLC
reduced
-29.77
-4,549
14,720
-%
Feb 14, 2024
VANGUARD GROUP INC
added
1.15
858,963
9,433,260
-%
Feb 14, 2024
Verition Fund Management LLC
sold off
-100
-63,692
-
-%
Feb 14, 2024
Graham Capital Management, L.P.
new
-
29,305
29,305
-%
Feb 14, 2024
SUSQUEHANNA INTERNATIONAL GROUP, LLP
added
187
1,822,110
2,677,610
-%
Feb 14, 2024
TWO SIGMA ADVISERS, LP
reduced
-3.75
9,285
207,017
-%

1–10 of 41

Are Funds Buying or Selling AKBA?

Are funds buying AKBA calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own AKBA
No. of Funds

Unveiling Akebia Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 13, 2024
vanguard group inc
4.04%
7,607,472
SC 13G/A
Feb 09, 2024
satter muneer a
8.6%
16,205,119
SC 13G/A
Feb 10, 2023
satter muneer a
8.2%
15,090,119
SC 13G/A
Feb 09, 2023
vanguard group inc
6.11%
11,238,870
SC 13G/A
Jan 20, 2023
state street corp
0.31%
571,936
SC 13G/A
Dec 19, 2022
satter muneer a
7.5%
13,864,330
SC 13G
Jul 08, 2022
blackrock inc.
2.4%
4,340,026
SC 13G
Jun 09, 2022
vanguard group inc
10.00%
18,359,420
SC 13G/A
Feb 10, 2022
state street corp
6.71%
11,743,461
SC 13G/A
Feb 09, 2022
vanguard group inc
7.56%
13,235,669
SC 13G/A

Recent SEC filings of Akebia Therapeutics Inc

View All Filings
Date Filed Form Type Document
Feb 13, 2024
8-K
Current Report
Feb 13, 2024
SC 13G/A
Major Ownership Report
Feb 09, 2024
SC 13G/A
Major Ownership Report
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading
Feb 02, 2024
4
Insider Trading

What is the Fair Value of AKBA?

Loading...
Disclaimer: Conduct thorough research and seek guidance from a certified financial advisor prior to finalizing any investment choices.

Peers (Alternatives to Akebia Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
33.4B
9.1B
-16.59% -47.80%
-9.64
3.66
-57.36% -129.46%
32.0B
-
-0.77% 465779.94%
-3.7K
218.4K
- -102.45%
19.5B
1.8B
-23.99% -31.71%
-44.27
10.66
76.23% 61.08%
16.7B
2.3B
-4.89% -18.90%
113.44
7.22
15.05% 75.21%
13.5B
3.7B
-7.62% -26.87%
22.67
3.67
8.87% 75.42%
MID-CAP
7.9B
272.9M
-2.06% 34.31%
-13.08
29.05
141.38% 4.43%
5.9B
107.9M
-3.85% 226.12%
-9.53
54.1
54.84% -25.61%
4.1B
631.9M
-12.60% 32.37%
-27.44
6.46
23.54% 31.53%
3.9B
223.4M
8.92% 47.81%
-19.25
17.39
-35.86% -26.24%
3.6B
240.7M
-19.08% -10.99%
-12.18
15.02
-1.03% -92.09%
SMALL-CAP
1.5B
348.4M
-3.38% -9.50%
23.56
4.2
81.69% -7.29%
472.8M
1.0B
-9.17% -57.89%
-0.86
0.45
-43.15% 58.48%
179.5M
4.9M
-14.18% -58.18%
-1.09
36.72
-57.57% 50.48%
120.1M
881.7K
289.54% 381.25%
-2.53
112.79
-77.61% -13.74%
4.2M
2.1M
7.69% 44.16%
-0.08
2.14
-13.45% 11.54%

Akebia Therapeutics Inc News

Latest updates
InvestorsObserver5 hours ago
InvestorsObserver15 Feb 202412:58 pm

Akebia Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
Income Statement (Quarterly)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Revenue2.3%42,046,00041,086,50040,127,00055,547,00048,714,000126,759,00061,699,00057,677,00048,756,00052,913,00052,304,00056,036,00059,988,00090,142,00088,478,00069,555,00091,977,000100,803,00072,666,00059,850,00053,169,000
Cost Of Revenue4.2%18,009,00017,284,00019,484,000-3,043,00038,281,00018,600,00031,344,00047,626,50015,944,00052,495,00034,606,00063,234,00030,345,000174,616,00027,713,00038,147,00038,263,00037,669,00031,257,0007,768,000-
Operating Expenses-22.9%37,073,00048,088,00045,581,00064,199,50060,838,00073,690,00088,848,00075,389,50087,698,00079,759,00082,634,00078,868,00087,738,00089,345,000119,890,000126,299,000109,619,000122,657,000117,378,000142,240,00081,012,000
  S&GA Expenses-16.0%22,710,00027,036,00025,053,00029,908,00031,887,00032,240,00044,566,00044,804,00046,357,00041,651,00041,328,00040,463,00040,171,00035,482,00037,983,00044,918,00034,178,00036,068,00034,291,00055,121,00010,378,000
  R&D Expenses-34.0%13,330,00020,197,00019,686,00032,098,00028,028,00026,027,00043,833,00029,556,00040,471,00037,214,00040,611,00037,578,00046,857,00052,819,00081,231,00080,412,00074,512,00085,694,00082,351,00087,052,00070,634,000
EBITDA Margin0%-0.32-0.32-0.32-0.29-0.92-0.92-1.22-1.28-1.79-1.69-1.45-1.27---------
Income Taxes-----------------1,752,000-1,277,000-845,000-2,757,000-28,338,000-
Earnings Before Taxes-------------88,384,000-59,959,000-175,751,000-60,747,000-96,235,000-55,862,000-59,015,000-75,178,000-88,392,000-26,047,000
EBT Margin0%-0.35-0.35-0.35-0.32-0.96-0.96-1.28-1.33-1.83-1.74-1.49-1.31---------
Net Income-29.7%-14,489,000-11,172,000-26,878,000-6,070,500-54,096,00029,449,000-63,509,000-69,862,000-59,544,000-83,038,000-69,580,000-87,000,000-59,959,000-175,751,000-60,747,000-94,483,000-54,585,000-58,170,000-72,421,000-60,054,000-26,047,000
Net Income Margin40.3%-0.22-0.36-0.21-0.32-0.54-0.55-1.25-1.33-1.42-1.35-1.52-1.30---------
Free Cashflow-297.4%-7,167,0003,631,000-17,540,000-54,679,00033,805,000-30,660,000-21,734,000-62,808,000-56,270,000-63,141,000-70,805,000-31,099,000---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Assets-7.4%235254281356444530542529602612629644676745788771795824891997404
  Current Assets-7.5%110118121185242308305271330331365371391449341310299316347468398
    Cash Equivalents-13.1%47.0054.0057.0090.0014814717815220924925522917224811815012387.0063.00107162
  Inventory-11.8%18.0021.0020.0022.0045.0040.0041.0037.0034.0038.0045.0061.0088.00105112116116122115114-
  Net PPE-9.0%4.004.005.005.006.006.006.007.007.008.008.009.009.009.0010.0010.0013.0011.0010.008.004.00
  Goodwill0.1%59.0059.0059.0059.0059.0059.0059.0059.0055.0055.0055.0055.0055.0055.0055.0055.0055.0055.0055.0055.00-
Liabilities-2.2%274281300351436471519455465437415397358375391376328304324361261
  Current Liabilities-13.5%80.0092.0088.00130193237258261189166173187181196214208223186203266177
  Long Term Debt87.2%35.0018.0026.0034.00----97.0097.0097.0096.0077.0076.0076.0076.00-----
    LT Debt, Current-66.7%8.0024.0024.0032.0066.0098.0098.0098.00-----------15.00-
    LT Debt, Non Current87.2%35.0018.0026.0034.00----97.0097.0097.0096.0077.0076.0076.0076.00-----
Shareholder's Equity0.1%1,5701,5681,5655.008.0059.0023.0074.00137175214244318370396393468519566636143
  Retained Earnings-0.9%-1,609-1,595-1,583-1,557-1,550-1,496-1,526-1,462-1,389-1,330-1,247-1,177-1,090-1,030-854-794-699-644-586-514-454
  Additional Paid-In Capital0.1%1,5701,5681,5651,5621,5591,5561,5491,5371,5271,5051,4611,4251,4081,4011,2511,1891,1671,1641,1531,151597
Shares Outstanding0.1%188188186184182182180177163161154138---------
Float------64.00---632---1,914---566---
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q12018Q42018Q3
Cashflow From Operations-297.4%-7,1673,631-17,540-54,67933,805-30,660-21,620-62,808-56,270-63,141-70,746-30,782-27,23737,220-89,589-92,13510,989-38,366-137,929-73,699-12,461
  Share Based Compensation-48.4%1,8003,4902,4893,0273,4006,9004,5364,6365,5936,5145,9926,0886,5926,8644,9164,9342,6132,2842,09412,0622,253
Cashflow From Investing--------114--20,00019,94159,683-49,937-49,99524522,28024,39054,033110,47316,71711,011
Cashflow From Financing100.6%50.00-8,000-15,966-1.00-32,937-9.0047,5455,40316,48237,36974,47730,5111,054142,80757,34894,4181958,804-14,44785.00354
  Buy Backs------------------426---

AKBA Income Statement

2023-09-30
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)
$ in Thousands
3 Months Ended9 Months Ended
Sep. 30, 2023
Sep. 30, 2022
Sep. 30, 2023
Sep. 30, 2022
Revenues    
Total revenues$ 42,046$ 48,714$ 138,427$ 236,702
Cost of goods sold    
Product8,99829,27028,45261,965
Amortization of intangible asset9,0119,01127,03227,032
Total cost of goods sold18,00938,28155,48488,997
Operating expenses:    
Research and development13,33028,02853,21497,888
Selling, general and administrative22,71031,88774,797108,693
License expense8647432,3812,323
Restructuring16918018114,711
Total operating expenses37,07360,838130,573223,615
Loss from operations(13,036)(50,405)(47,630)(75,910)
Other income (expense)    
Interest expense(1,410)(3,952)(4,614)(14,051)
Other (expense) income(43)1,1672292,712
Loss on extinguishment of debt0(906)0(906)
Loss on termination of lease00(524)0
Net (loss) income, basic(14,489)(54,096)(52,539)(88,155)
Net (loss) income, diluted(14,489)(54,096)(52,539)(88,155)
Comprehensive loss$ (14,489)$ (54,096)$ (52,539)$ (88,155)
Net loss per share:    
Basic (in dollars per share)$ (0.08)$ (0.29)$ (0.28)$ (0.48)
Diluted (in dollars per share)$ (0.08)$ (0.29)$ (0.28)$ (0.48)
Weighted average common shares outstanding:    
Basic (in shares)188,306,350183,882,446186,643,878182,375,443
Diluted (in shares)188,306,350183,882,446186,643,878182,375,443
Product revenue, net    
Revenues    
Total revenues$ 40,118$ 41,989$ 117,068$ 126,670
License, collaboration and other revenue    
Revenues    
Total revenues$ 1,928$ 6,725$ 21,359$ 110,032

AKBA Balance Sheet

2023-09-30
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($)
$ in Thousands
Sep. 30, 2023
Dec. 31, 2022
Current assets:  
Cash and cash equivalents$ 46,529$ 90,466
Inventories18,44221,568
Accounts receivable, net22,59240,284
Prepaid expenses and other current assets22,03932,864
Total current assets109,602185,182
Property and equipment, net4,0235,214
Operating right-of-use assets13,41429,158
Intangible asset, net45,05372,084
Goodwill59,04459,044
Other long-term assets3,8625,372
Total assets234,998356,054
Current liabilities:  
Accounts payable9,03818,021
Accrued expenses and other current liabilities62,66475,777
Short-term deferred revenue03,738
Current portion of long-term debt8,00032,000
Total current liabilities79,702129,536
Deferred revenue, net of current portion43,29643,296
Long-term operating lease liabilities10,22728,961
Embedded debt derivative760760
Long-term debt, net34,61334,078
Liability related to sale of future royalties56,06157,484
Refund liability to customer40,34640,992
Other long-term liabilities9,41515,717
Total liabilities274,420350,824
Commitments and contingencies (Note 12)
Stockholders' (deficit) equity:  
Preferred stock $0.00001 par value, 25,000,000 shares authorized; no shares issued and    outstanding at September 30, 2023 and December 31, 202200
Common stock $0.00001 par value; 350,000,000 shares authorized at September 30, 2023 and December 31, 2022; 188,313,807 and 184,135,714 shares issued and outstanding at September 30, 2023 and December 31, 2022, respectively22
Additional paid-in capital1,570,1341,562,247
Accumulated other comprehensive income66
Accumulated deficit(1,609,564)(1,557,025)
Total stockholders' (deficit) equity(39,422)5,230
Total liabilities and stockholders' (deficit) equity$ 234,998$ 356,054
AKBA
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) in dialysis-dependent and non-dialysis dependent adult patients. It also offers Auryxia, a ferric citrate that is used to control the serum phosphorus levels in adult patients with DD-CKD on dialysis; and the treatment of iron deficiency anemia in adult patients with CKD not on dialysis. Akebia Therapeutics, Inc. has collaboration agreements with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of vadadustat in Japan and other Asian countries, as well as research and license agreement with Janssen Pharmaceutica NV for the development and commercialization of hypoxia-inducible factor prolyl hydroxylase targeted compounds worldwide. The company was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEwww.akebia.com
 EMPLOYEES204

Akebia Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Akebia Therapeutics Inc? What does AKBA stand for in stocks?

AKBA is the stock ticker symbol of Akebia Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Akebia Therapeutics Inc (AKBA)?

As of Wed Feb 21 2024, market cap of Akebia Therapeutics Inc is 267.51 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers.

What is the fair value of AKBA stock?

You can check AKBA's fair value in chart for subscribers. The fair value of Akebia Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Akebia Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for AKBA so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Akebia Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether AKBA is over valued or under valued. Whether Akebia Therapeutics Inc is cheap or expensive depends on the assumptions which impact Akebia Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AKBA.

What is Akebia Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Feb 21 2024, AKBA's PE ratio (Price to Earnings) is -4.56 and Price to Sales (PS) ratio is 1.06. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AKBA PE ratio will change depending on the future growth rate expectations of investors.